DNM2 and cancer: The same might hold true for components of the cytoskeleton, since TUBB, ACTB, and ACTG1 are all included in the candidate gene list, which would be in line with the frequently observed increased expression of cytoskeletal proteins in cancer and associations with poor outcome and chemoresistance [52, 53].